



Viscoelastic Testing is Superior to Conventional Lab based Coagulation Testing for Hemostatic Monitoring during Traumatic Hemorrhage: PRO!

Melissa Cushing, MD

Professor of Pathology and Laboratory Medicine Division Director of Transfusion Medicine and Cellular Therapy Executive Vice Chair for Clinical Affairs, Dept of Pathology and Laboratory Medicine





disclosures

- ♦ I am on the Scientific Advisory Board for Cerus and Haemonetics
- ♦ I have served as a consultant for Octapharma



Limitations of Conventional Coagulation Testing

- Poorly reflect in vivo coagulation
 - ♦ PT/PTT
 - ♦ Tests run on <u>plasma</u> samples, removes interaction of platelets, red cells, WBC
 - ♦ Do not estimate overall clot strength test read at the initiation of fibrin polymerization when less than 5% of total thrombin generated
 - ♦ Platelet counts give no information about underlying platelet function
- Lack sensitivity and specificity in acute bleeding (PT and PTT designed for drug monitoring)
- ♦ Significant time delay in getting results (45 minutes-1 hour in most hospitals)
- Conventional coagulation tests cannot evaluate fibrinolysis

precision medicine = rapid, goal directed therapy


- VET analyzes all components of the clot (except the endothelium and VWF) and directs therapy to a specific deficiency
- VET can provide simple, rapid evaluation for hyperfibrinolysis
- VET can be rapidly available in 5-10 minutes at the patient's bedside for immediate decision-making

time matters in trauma





2022 Approach in trauma: Bleeding 300 mL per 30 min




Rapid goal-directed therapy with POC testing in 20 minutes = 250 mL blood loss before definitive treatment




- -Trauma-induced coagulopathy is an umbrella term that includes multiple mechanisms of hemostasis derangement, as well as later thrombotic complications.
- -Coagulopathy dependent on mechanism of injury, time from injury to admission, volume of fluids given, and other factors
- -One size does not fit all. Tailored therapy is necessary.

https://criticalcarenow.com/

Slide adapted from Karim Brohi



Supportive Literature – Level of the evidence?



Meta-analysis

VET reduces mortality and numbers of transfused blood products Meta-analysis – Grade

Thromboelastography (TEG) or rotational thromboelastometry (ROTEM) to monitor haemostatic treatment in bleeding patients: a systematic review with meta-analysis and trial sequential analysis

A. Wikkelsø X, J. Wetterslev, A. M. Møller, A. Afshari

First published: 04 January 2017 | https://doi.org/10.1111/anae.13765 | Cited by: 36

Forrest plot of primary outcome: mortality at longest follow-up

	TEG or ROTEM		Control		Risk ratio			Risk ratio			
Study or subgroup	Events	Total	Events	Total	Weight	M-H,Fixed, 95% (CI	М-Н,	Fixed, 95	% CI	
Ak 2009	3	114	2	119	7.5%	1.45 [0.25, 8.50]	_			
Girdauskas 2010	4	27	5	29	17.8%	0.86 [0.26, 2.87]	_	-		
Nakayama 2015	0	50	0	50		Not estimable	е				
Paniagua 2011	3	26	4	18	17.4%	0.52 [0.13, 2.05]		•		
Royston 2001	0	30	0	30		Not estimable	Э				
Shore-Lesserson 1999	0	53	2	52	9.3%	0.20 [0.01, 3.99] —	-	_	_	
Wang 2010	2	14	3	14	11.1%	0.67 [0.13, 3.40]	-	-	-	
Weber 2012	2	50	10	50	36.9%	0.20 [0.05, 0.87]		_		
Total (95% CI)		364		353	100.0%	0.52 [0.28, 0.95]	•	•		
Total events	14		26								
Heterogeneity χ^2 = 4.08, d.f. = 5 (p = 0.54): I^2 = 0%							—				——
Test for overall effect: Z =	2.13 (p = 0)	.03)					0.002	0.1	1	10	500
							Favours	TEG&ROTE	М	Favours co	ntrol

Wikkelso et al. Anaesthesia 2017, 72, 519-531

The use of viscoelastic haemostatic assays in goal-directing treatment with allogeneic blood products – A systematic review and meta-analysis

Mathilde Fahrendorff^{1*}, Roberto S. Oliveri¹ and Pär I. Johansson^{1,2,3}


Meta-analysis- Grade IA

Results: Fifteen RCTs (*n* = 1238 patients) were included. Nine trials referred to <u>cardiothoracic patients</u>, one to <u>liver</u> transplantation, one to surgical excision of <u>burn</u> wounds and one to <u>trauma</u>. One trial was conducted with cirrhotic patients, one with patients undergoing scoliosis surgery while one trial randomised treatment in post-partum females presenting with bleeding. The amount of transfused red blood cells (RBCs), fresh frozen plasma (FFP) and bleeding volume was found to be significantly reduced in the VHA-guided groups, whereas no significant difference was found for platelet transfusion requirements or mortality.

Clinical trials

Goal-directed Hemostatic Resuscitation of Trauma-induced Coagulopathy:

A Pragmatic Randomized Clinical Trial Comparing a Viscoelastic Assay to Conventional Coagulation Assays



cbslocal.com

Clinical Trials -Grade IB

Conclusions—Utilization of a goal-directed, TEG-guided MTP to resuscitate severely injured patients improves survival compared with an MTP guided by CCA and utilizes less plasma and platelet transfusions during the early phase of resuscitation.

Ann Surg. 2016 June; 263(6): 1051-1059.

iTACTIC Subgroup Analysis

- 28-day mortality In coagulopathic group (PTr> 1.2):
 - -CCT: 55%
 - -TEG/ROTEM: 41%

28-day mortality in patients who required massive transfusion (>10 RBCs)

- -CCT: 47%
- -TEG/ROTEM: 38%

iTACTIC Subgroup Analysis – Severe Brain Injury Group

- 19% of major hemorrhage patients also had severe traumatic brain injury:
 - -28 day mortality:

•CCT: 74%

•ROTEM/TEG: 44%

ITACTIC

• 10% lower rate of thrombotic events in VET vs CCT.

Caveats for interpreting iTACTIC results

- Most of the participating centers didn't use VET augmented MHP in their clinical trauma protocols routinely before iTACTIC (did they follow protocols?)
- Assumption that VET could reduce mortality or massive transfusion from 28% to 15% is very ambitious, especially since only 29% were even mildly coagulopathic (PTr > 1.2) and in the study overall mortality was only 16% for the entire cohort and massive transfusion was only seen in 27% of patients.
- Inaccurate to use CCT to define coagulopathy (PTr > 1.2 is close to reference range)
- Patients who are not coagulopathic are unlikely to see benefit from any type of coag testing
 - Very likely study is underpowered because of lower than expected incidence of TIC
- All patients may not benefit from a VET guided protocol (especially if they aren't coagulopathic)
- Took 1 hour from the first guided VET intervention to get products (products all frozen in the lab)

Retrospective Studies

Retrospective trials evaluating utility of VET in trauma

Date	Study	Patient Population	Findings	VET
2012	Tapia N et al VET vs MTP Before/after MTP implemented	Massively transfused penetrating trauma at a single urban trauma center in U.S. N=289	MTP equivalent for patients receiving 6U or more RBC or blunt trauma; MTP worsened mortality in 10 or more units penetrating vs. VET	TEG
2018	Deng Q et al Propensity score matched	Pediatric Trauma at 6 institutes in China N=332	Earlier treatment, less plasma tx, decreased LOS for VET protocol	ROTEM
2019	Guth C. et al Before/after (VET + DCR + TXA)	Single center in France Blunt and penetrating N=380	VET decreased use of blood products, need for massive transfusion, and improved survival	
2019	Cohen J et al Predict MTP and identify ACT	Military trauma in Afghanistan N=40	Integrating ROTEM into early identification of ATC increases detection	ROTEM
2020	Lammers DT et al VET vs CCT Trauma Registry	Dept of Defense N=3320	VET associated with decreased mortality	ROTEM

RESEARCH

Open Access

The European guideline on management of major bleeding and coagulopathy following trauma: fifth edition



Donat R. Spahn¹, Bertil Bouillon², Vladimir Cerny^{34,56}, Jacques Duranteau², Daniela Filipescu⁸, Beverley J. Hunt⁹, Radko Komadina⁹, Marc Maegel⁴, Giuseppe Nardi¹², Louis Riddez¹³, Charles-Marc Samama¹⁴, Jean-Louis Mincent¹⁵ and Rolf Rossaint¹⁶

ACS TQIP
MASSIVE
TRANSFUSION
IN TRAUMA
GUIDELINES

Guidelines

What does Dr. Callum recommend?

Randomized Controlled Trial > Clin Chim Acta. 2019 Aug;495:253-262. doi: 10.1016/j.cca.2019.04.066. Epub 2019 Apr 17.


A comparative study of viscoelastic hemostatic assays and conventional coagulation tests in trauma patients receiving fibrinogen concentrate

Henry T Peng ¹, Bartolomeu Nascimento ², Homer Tien ², Jeannie Callum ², Sandro Rizoli ³, Shawn G Rhind ⁴, Andrew Beckett ⁵

Conclusions: TEG and ROTEM detected increases in clot strength following early use of fibrinogen. ROTEM also detected changes in coagulation time and clot lysis. Both were better than CCTs for monitoring coagulation profiles and predicting transfusion requirements.

VET are performed by professionals

But... we have choices



Turnaround time is critical for traumatic

> Transfusion. 2010 Dec;50(12):2547-52. c

Development of a rapid panel

Wayne L Chandler ¹, Chris Ferrell, Sara Trin

Jeannie L. Callum, BA, MD, FRCPC, CTBS

Clinical Pathology

 $e\hbox{-}mail\hbox{:} jeannie.callum@sunnybrook.ca$

Sandro Rizoli, MD, PhD, FRCSC, FACS

Department of Surgery

 $Sunny brook\ Health\ Sciences\ Centre$

Toronto

Jacob Pendergrast, MD, FRCPC

University Health Network Toronto, Ontario, Canada The 10 modifications made to standard practice were as follows:

- Emergency hemorrhage panels prioritized over all other STAT and routine samples.
- 2. PTT removed from their hemorrhage panel.
- 3. Thrombin time (TT) removed from the hemorrhage panel.
- Samples moved directly to testing area upon arrival to the laboratory, with computer entry and accessioning labels performed while the sample was commencing centrifugation.
- 5. Centrifugation time shortened from 8 minutes at $2000 \times g$ to 2 minutes at $4440 \times g$.
- Checks for clots eliminated after determining that clots in samples did not cause a clinically significant impact on the PT result and would only result in one erroneous fibrinogen result (normal to falsely low reading) in 2300 samples.
- Checks for hemolysis eliminated after determining that no clinically significant impact on the PT or the fibrinogen result was noted.
- 8. Critical results not repeated before release.
- All results, critical or not, called to the clinical team immediately.
- 10. Calibration curve for fibrinogen extended down to 53 mg/dL. If the result fell below this level, the result was reported as less than 53 mg/dL instead of doing the standard dilutions and repeat testing to get an "exact" result.

age

Too Complicated

And sample must still be delivered to a Central Lab

So how do we successfully deploy VET in trauma?


- 1) Ensure accurate testing
 - a. Proper sample collection (fill the citrate tube correctly)
 - b. Proper transport (pneumatic tube may affect results)
 - c.Proper test performance with trained operators, proper QC and calibration of instrument
- 2)Integrate VET results with clinical decision-making (algorithm-based approach), also taking in account clinical factors
- 3)Use data driven thresholds/triggers for transfusions

Trauma
Bleeding
Algorithm

4) Utilize algorithms

Weill Cornell Medicine


ROTEM **Bleeding** management



Bleeding & abnormal ROTEM:

→ Keep Temperature > 36°C, keep pH > 7.3 and keep Ionized Calcium >1.1 mmol/l

1. Weak clot strength



Re-assess ROTEM 10 mins after each coag therapy (or when picking up next MTP cooler

D bushing/Haus 2016

So how do we successfully deploy VET in trauma?

- 5) Ensure an iterative testing algorithm, fix problem and reassess to ensure coagulopathy is resolved
- 6) Provide immediate access to results (remote viewing capability from anywhere)
- 7) Remind physicians that VET is conducted under ideal lab settings (enough ionized Ca, normothermia, normal pH), patient may not be in this condition.
- 8) Educate anesthesiologists trauma surgeons, and other team members in VET interpretation

Ongoing education and algorithm reinforcement are important!




If you build it, they will come?









I know how I want to treat my patient.





